全文获取类型
收费全文 | 948篇 |
免费 | 43篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 26篇 |
儿科学 | 41篇 |
妇产科学 | 16篇 |
基础医学 | 134篇 |
口腔科学 | 6篇 |
临床医学 | 127篇 |
内科学 | 168篇 |
皮肤病学 | 13篇 |
神经病学 | 81篇 |
特种医学 | 49篇 |
外科学 | 74篇 |
综合类 | 15篇 |
一般理论 | 2篇 |
预防医学 | 84篇 |
眼科学 | 5篇 |
药学 | 50篇 |
中国医学 | 5篇 |
肿瘤学 | 96篇 |
出版年
2023年 | 2篇 |
2022年 | 6篇 |
2021年 | 15篇 |
2020年 | 9篇 |
2019年 | 16篇 |
2018年 | 10篇 |
2017年 | 11篇 |
2016年 | 9篇 |
2015年 | 11篇 |
2014年 | 13篇 |
2013年 | 46篇 |
2012年 | 78篇 |
2011年 | 75篇 |
2010年 | 35篇 |
2009年 | 30篇 |
2008年 | 56篇 |
2007年 | 68篇 |
2006年 | 76篇 |
2005年 | 65篇 |
2004年 | 60篇 |
2003年 | 63篇 |
2002年 | 55篇 |
2001年 | 24篇 |
2000年 | 13篇 |
1999年 | 7篇 |
1998年 | 6篇 |
1997年 | 12篇 |
1996年 | 4篇 |
1995年 | 7篇 |
1994年 | 7篇 |
1993年 | 6篇 |
1992年 | 6篇 |
1991年 | 11篇 |
1990年 | 7篇 |
1989年 | 6篇 |
1988年 | 5篇 |
1987年 | 9篇 |
1986年 | 2篇 |
1985年 | 4篇 |
1983年 | 5篇 |
1982年 | 2篇 |
1977年 | 3篇 |
1974年 | 3篇 |
1973年 | 2篇 |
1972年 | 3篇 |
1970年 | 2篇 |
1969年 | 2篇 |
1967年 | 4篇 |
1940年 | 2篇 |
1900年 | 2篇 |
排序方式: 共有992条查询结果,搜索用时 15 毫秒
11.
12.
13.
14.
15.
R Marcy M A Quermonne J Raoul B Nammathao 《Progress in neuro-psychopharmacology & biological psychiatry》1987,11(1):35-43
SCR-hypoxia test is based on the possible recovery by treatments tested of the SCR depressed through hypoxia. All drugs were administered intraperitoneally to male and female Swiss Orl mice randomized into groups of 10. SCR is measured with a palmar skin conductance-meter, in response to a photostimulus. This apparatus takes place in a cell allowing working in a definite hypoxic atmosphere, at a normal pressure. 15 drugs clinically used in various pathological states related to hypoxia are tested. SCR magnitude is recovered by the "antihypoxic" drugs. Specificity, sensitivity and quantifying value of the test are discussed leading to propose the SCR-hypoxia test in the design of new potentially antihypoxic drugs. 相似文献
16.
17.
Everett E Vokes Kerstin Stenson Fred R Rosen Merrill S Kies Alfred W Rademaker Mary Ellyn Witt Bruce E Brockstein Marcy A List Bing Bing Fung Louis Portugal Bharat B Mittal Harold Pelzer Ralph R Weichselbaum Daniel J Haraf 《Journal of clinical oncology》2003,21(2):320-326
PURPOSE: The paclitaxel, fluorouracil, and hydroxyurea regimen of paclitaxel, infusional fluorouracil, hydroxyurea, and twice-daily radiation therapy (TFHX) administered every other week has resulted in 3-year survival rates of 60% of stage IV patients. Locoregional and distant failure rates were 13% and 23%, respectively. To reduce distant failure rates, we added a brief course of induction chemotherapy to TFHX. PATIENTS AND METHODS: Sixty-nine patients received six weekly doses of carboplatin (AUC2) and paclitaxel (135 mg/m2) followed by five cycles of TFHX. RESULTS: Ninety-six percent had stage IV disease. Response to induction chemotherapy was partial response 52% and complete response (CR) 35%. Symptomatically, there was a significant reduction in mouth and throat pain. The most common grade 3 or 4 toxicity was neutropenia (36%). Best response following completion of TFHX was CR in 83%. Toxicities of TFHX consisted of grade 3 or 4 mucositis (74% and 2%) and dermatitis (47% and 14%). At a median follow-up of 28 months, locoregional or systemic disease progression were each noted in five patients. The overall 3-year progression-free survival was 80% (95% confidence interval [CI], 71% to 90%), and the 2- and 3-year overall survival rates were 77% (95% CI, 66% to 87%) and 70% (95% CI, 59% to 82%), respectively. At 12 months, five patients were completely feeding-tube dependent. CONCLUSION: Administration of carboplatin and paclitaxel before TFHX chemoradiotherapy results in high response activity and may decrease distant failure rates. Overall survival, progression, and organ preservation/functional outcome data support definitive evaluation of this approach. 相似文献
18.
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). 总被引:9,自引:0,他引:9
Rogerio C Lilenbaum James E Herndon Marcy A List Chris Desch Dorothy M Watson Antonius A Miller Stephen L Graziano Michael C Perry Wayne Saville Philippe Chahinian Jane C Weeks Jimmie C Holland Mark R Green 《Journal of clinical oncology》2005,23(1):190-196
PURPOSE: We compared the efficacy of combination chemotherapy versus single-agent therapy in patients with advanced non-small-cell lung cancer. PATIENTS AND METHODS: A total of 561 eligible patients were randomly assigned to receive paclitaxel alone or in combination with carboplatin. RESULTS: The response rate was 17% in the paclitaxel arm and 30% in the carboplatin-paclitaxel arm (P < .0001). Median failure-free survival was 2.5 months in the paclitaxel arm and 4.6 months in the carboplatin-paclitaxel arm (P = .0002). Median survival times were 6.7 months (95% CI, 5.8 to 7.8) and 8.8 months (95% CI, 8.0 to 9.9), and 1-year survival rates were 32% (95% CI, 27% to 38%), and 37% (95% CI, 32% to 43%), respectively. The overall survival distributions were not statistically different: hazard ratio = 0.91 (95% CI, 0.77 to 1.17; P = .25). Hematological toxicity and nausea were more frequent in the combination arm, but febrile neutropenia and toxic deaths were equally low in both arms. There was no significant survival difference in elderly patients. Performance status 2 patients treated with combination chemotherapy had a better survival rate than those treated with single-agent therapy (P = .019). CONCLUSION: Combination chemotherapy improves response rate and failure-free survival compared with single-agent therapy, but there was no statistically significant difference in the primary end point of overall survival. The results in elderly patients were similar to younger patients. Performance status 2 patients had a superior outcome when treated with combination chemotherapy. 相似文献
19.
20.